Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 28 Genitourinary 26 Gastrointestinal 26 Thoracic 17 Gynecologic 14 CNS 7 Head & Neck 6 Lymphoid 5 Sarcoma 4 Other hematologic neoplasm 4 Dermatologic 4 Tumor-Agnostic 2 Other 2 Endocrine 2 Plasma cell 1 Other neoplasm 1 NET 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 18 Everolimus 13 Temozolomide 12 Nivolumab 10 pembrolizumab 9 cabozantinib 8 Capecitabine 8 Sunitinib 7 lenvatinib 5 Magnetic Resonance Spectroscopy 5 Etoposide 5 lanreotide 4 gallium Ga 68 dotatate 4 Specimen Handling 4 Ipilimumab 4 Cisplatin 4 Carboplatin 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 telotristat ethyl 3 surufatinib 3 pazopanib 3 avelumab 3 Octreotide 3 Injections 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 Bevacizumab 3 sintilimab 2 fosbretabulin 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Metformin × NET × Clear all

NCT02279758 2014-10-31

MetNet

Instituto do Cancer do Estado de São Paulo

Phase 2 Unknown

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡